BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 18076128)

  • 1. Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model.
    El-Gogo S; Staib C; Lasarte JJ; Sutter G; Adler H
    J Gene Med; 2008 Feb; 10(2):177-86. PubMed ID: 18076128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant murine gammaherpesvirus 68 (MHV-68) as challenge virus to test efficacy of vaccination against chronic virus infections in the mouse model.
    El-Gogo S; Staib C; Meyr M; Erfle V; Sutter G; Adler H
    Vaccine; 2007 May; 25(20):3934-45. PubMed ID: 17433507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice.
    Zeng R; Li G; Ling S; Zhang H; Yao Z; Xiu B; He F; Huang R; Wei L
    Antiviral Res; 2009 Oct; 84(1):23-30. PubMed ID: 19646486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
    Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP
    J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunity and protection by adoptive transfer of dendritic cells transfected with hepatitis C NS3/4A mRNA.
    Yu H; Babiuk LA; van Drunen Littel-van den Hurk S
    Vaccine; 2007 Feb; 25(10):1701-11. PubMed ID: 17240490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HCV-core and NS3 antigens play disparate role in inducing regulatory or effector T cells in vivo: Implications for viral persistence or clearance.
    Krishnadas DK; Li W; Kumar R; Tyrrell DL; Agrawal B
    Vaccine; 2010 Feb; 28(9):2104-14. PubMed ID: 20045096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene.
    Frelin L; Ahlén G; Alheim M; Weiland O; Barnfield C; Liljeström P; Sällberg M
    Gene Ther; 2004 Mar; 11(6):522-33. PubMed ID: 14999224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins.
    Haller AA; Lauer GM; King TH; Kemmler C; Fiolkoski V; Lu Y; Bellgrau D; Rodell TC; Apelian D; Franzusoff A; Duke RC
    Vaccine; 2007 Feb; 25(8):1452-63. PubMed ID: 17098335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterologous T cells can help restore function in dysfunctional hepatitis C virus nonstructural 3/4A-specific T cells during therapeutic vaccination.
    Chen A; Ahlén G; Brenndörfer ED; Brass A; Holmström F; Chen M; Söderholm J; Milich DR; Frelin L; Sällberg M
    J Immunol; 2011 May; 186(9):5107-18. PubMed ID: 21430225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in hepatitis C virus NS3 antigen.
    Martin P; Parroche P; Chatel L; Barretto C; Beck A; Trépo C; Bain C; Lone YC; Inchauspé G; Fournillier A
    J Med Virol; 2004 Nov; 74(3):397-405. PubMed ID: 15368525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus.
    Puig M; Mihalik K; Tilton JC; Williams O; Merchlinsky M; Connors M; Feinstone SM; Major ME
    Hepatology; 2006 Sep; 44(3):736-45. PubMed ID: 16941702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with protein-transduced dendritic cells elicits a sustained response to hepatitis C viral antigens.
    Kuzushita N; Gregory SH; Monti NA; Carlson R; Gehring S; Wands JR
    Gastroenterology; 2006 Feb; 130(2):453-64. PubMed ID: 16472599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein.
    Mansilla C; Gorraiz M; Martinez M; Casares N; Arribillaga L; Rudilla F; Echeverria I; Riezu-Boj JI; Sarobe P; Borrás-Cuesta F; Prieto J; Lasarte JJ
    J Hepatol; 2009 Sep; 51(3):520-7. PubMed ID: 19596480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multigenotype HCV-NS3 recombinant vaccinia viruses as a model for evaluation of cross-genotype immunity induced by HCV vaccines in the mouse.
    Eisenbach C; Freyse A; Lupu CM; Weigand K; Ernst E; Hoyler B; Stremmel W; Bugert JJ; Encke J
    Vaccine; 2006 Jun; 24(24):5140-8. PubMed ID: 16713033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HCV-NS3 Th1 minigene vaccine based on invariant chain CLIP genetic substitution enhances CD4(+) Th1 cell responses in vivo.
    Gao M; Wang HP; Wang YN; Zhou Y; Wang QL
    Vaccine; 2006 Jun; 24(26):5491-7. PubMed ID: 16725235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes.
    Ahlen G; Nystrom J; Pult I; Frelin L; Hultgren C; Sallberg M
    J Infect Dis; 2005 Dec; 192(12):2112-6. PubMed ID: 16288375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus.
    Arribillaga L; Sarobe P; Arina A; Gorraiz M; Borrás-Cuesta F; Ruiz J; Prieto J; Chen L; Melero I; Lasarte JJ
    Vaccine; 2005 May; 23(27):3493-9. PubMed ID: 15855007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins.
    Satoi J; Murata K; Lechmann M; Manickan E; Zhang Z; Wedemeyer H; Rehermann B; Liang TJ
    J Virol; 2001 Dec; 75(24):12121-7. PubMed ID: 11711603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel hepatitis C virus vaccine approach using recombinant Bacillus Calmette-Guerin expressing multi-epitope antigen.
    Wei SH; Yin W; An QX; Lei YF; Hu XB; Yang J; Lu X; Zhang H; Xu ZK
    Arch Virol; 2008; 153(6):1021-9. PubMed ID: 18421415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Priming with two DNA vaccines expressing hepatitis C virus NS3 protein targeting dendritic cells elicits superior heterologous protective potential in mice.
    Guan J; Deng Y; Chen H; Yin X; Yang Y; Tan W
    Arch Virol; 2015 Oct; 160(10):2517-24. PubMed ID: 26215441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.